Evaluating the Use of the Qidni/D Hemodialysis System by Subjects With End-Stage Renal Disease

Inclusion Criteria: * Subject has provided informed consent. * Subject is at least 18 years and less than 75 years of age. * Subject has end-stage renal disease adequately treated by maintenance dialysis and has been deemed stable for at least three months by his/her treating nephrologist. * Subject has a well-functioning and stable vascular access that allows a blood flow of at least 300 ml/min for conventional treatment or 200-250 mL/min for nocturnal hemodialysis treatment. * Subject understands the nature of the procedures and the requirements of the study protocol. * Subject is willing and able to comply with the protocol requirements and return to the treatment center for all required treatments and clinical evaluations. * Subject has no childbearing potential or the Subject affirms they are not pregnant. Subject affirms using contraception measures to prevent potential pregnancies during the study period. Exclusion Criteria: * Subject is unable to read English. * Subject has dementia or lacks capacity for self-care. * Life expectancy less than 12 months from first study procedure. * Subject unable to understand or cooperate with the hemodialysis nurse and dialysis care team. * Subject has a documented history of non-adherence to dialysis therapy that would prevent successful completion of the study. * Subject has had a recent major cardiovascular adverse event within the last 3 months. * Subject has a persistent pre-dialysis sitting systolic blood pressure less than 100 mmHg despite medical therapy. * Subject has ongoing, symptomatic intra-dialytic hypotension requiring medical intervention. * Subject has an active infection requiring antibiotics within the last 7 days. * Subject with fluid overload due to intractable ascites secondary to liver cirrhosis. * Subject is seroreactive for Hepatitis B Surface Antigen. * Subject has a history of adverse reactions to dialyzer membrane material. * Subject is participating in another investigative drug or device clinical study related to dialysis which conflicts with the execution of this study. * Subject is scheduled to receive an organ transplant during the course of the study: paired exchange or living donor. * Subject has a life-threatening malignancy actively receiving treatment that would prevent successful completion of the study protocol. * Any other documented condition that the Investigator feels would prevent the Subject from successful inclusion in the study. * Subject has an active viral infection (eg. COVID-19). * Subject is on peritoneal dialysis.